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ORIGINAL ARTICLE

The Utility of HAS-BLED Score in Predicting the
Bleeding Risk of Atrial Fibrillation Patients
Undergoing Percutaneous Coronary Intervention
Receiving Anticoagulation and Dual Anti-platelet
Therapy: A Single Center Retrospective Cohort Study
Adrian Yin-Cheung Luk*, Jaclyn Chi-Lin Chan
Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong

Abstract
Background: The Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly and Drugs/alcohol (HAS-BLED) score is a validated bleeding risk prediction tool in
patients with atrial ﬁbrillation taking oral anticoagulation. Its predictive value in patients with atrial ﬁbrillation undergoing percutaneous coronary intervention receiving combination of anticoagulation and antiplatelet therapy is unknown. This retrospective cohort study sought to validate the accuracy of HAS-BLED score in predicting the bleeding
risk in patients with atrial ﬁbrillation who underwent percutaneous coronary intervention receiving both anticoagulation and dual antiplatelet therapy.
Method: We calculated HAS-BLED score in 186 patients with AF undergoing coronary stenting and assessed the
incidence of bleeding events deﬁned by the International Society on Thrombosis and Hemostasis (ISTH) bleeding scale.
Results: The mean age of the patients was 72. The proportion of male to female was 2.93: 1. Using a HAS-BLED cut off
of ≥3, a signiﬁcantly higher incidence of bleeding was detected in the high HAS-BLED compared to the low HAS-BLED
cohort. Such difference of bleeding incidence remained signiﬁcant in the triple therapy subgroup whereas it became
statistically insigniﬁcant in the dual-antiplatelet subgroup. The predictive performance was modest (AUC 0.673, 95% CI,
0.535e0.811, p ¼ 0.028).
Conclusion: HAS-BLED score is a simple and useful tool to predict bleeding risk in a group of atrial ﬁbrillation patients
who require triple therapy after percutaneous coronary intervention.
Keywords: HAS-BLED score, Atrial ﬁbrillation, Antithrombotic therapy, Percutaneous coronary intervention

Introduction
trial ﬁbrillation and coronary artery disease
are common coexisting cardiac problems.
For patients undergoing percutaneous coronary
intervention, it has been well proven that a duration
of dual anti-platelet therapy can reduce the risk of
stent thrombosis. For patients with atrial ﬁbrillation,

A

anticoagulation by Vitamin K antagonist or nonvitamin K oral anticoagulants can reduce the risk of
cardioembolic stroke.
This leads to a challenging situation in atrial
ﬁbrillation patients who require percutaneous coronary intervention. They need to receive both dual
anti-platelet therapy and anticoagulation to prevent
stent thrombosis and cardioembolic stroke. This
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combined triple therapy poses a high risk of fatal
and non-fatal bleeding complications.
The European Society of Cardiology (ESC)
guideline on myocardial revascularization in 2018
[1] recommended that triple therapy with aspirin,
clopidogrel and an oral anticoagulant should be
prescribed for 1 month and up to 6 months if
ischemic risk outweighs the bleeding risk (Class IIa
B). In patients whose bleeding risk outweighs the
ischemic risk, dual therapy with clopidogrel plus an
oral anticoagulant should be considered as an
alternative to 1 month of triple therapy (Class IIa).
Non-vitamin K oral anticoagulant is preferred over
vitamin K antagonist. The guideline suggested that
the bleeding risk should be estimated using HASBLED or ABC score.
The Hypertension, Abnormal renal/liver function,
Stroke, Bleeding history or predisposition, Labile
international normalized ratio, Elderly and Drugs/
alcohol (HAS-BLED) score was developed in 2010
with data derived from 3978 patients in the Euro
Heart Survey [2]. It has been well validated in predicting bleeding risk in patients taking oral anticoagulants with atrial ﬁbrillation [3,4]. Little was
known about its accuracy in assessing bleeding risks
in patients with atrial ﬁbrillation undergoing
percutaneous coronary intervention requiring both
antiplatelet and anticoagulation therapy. There
were only a few studies looking into this aspect.
This study aims to evaluate and validate the accuracy of HAS-BLED score in predicting the bleeding
risk in patients with atrial ﬁbrillation undergoing
percutaneous coronary intervention and receiving
both anticoagulation and dual antiplatelet therapy.

Methods
Study design and methods
This was a single center, retrospective cohort study
performed at Kwong Wah Hospital in Hong Kong.
Patients aged 18 years or above with paroxysmal or
permanent atrial ﬁbrillation who underwent percutaneous coronary intervention from January 2007 to
December 2017 and received either triple therapy
(dual anti-platelet therapy and oral anticoagulation)
or dual anti-platelet therapy upon discharge were
identiﬁed using the Cardisys cardiology management system record. Patients who received oral anticoagulant plus one single anti-platelet therapy were
not included in this study. Patients who died within
the index hospitalization of percutaneous coronary
intervention were excluded. Patients who defaulted
subsequent medical follow up were excluded. Patients who did not follow the originally planned

duration of triple therapy and anti-platelet therapy
were also excluded.
The baseline characteristics including age, sex,
smoking and drinking history, hypertension, diabetes, hyperlipidemia, renal function, history of
ischemic stroke and intracranial hemorrhage, type of
oral anticoagulation and anti-platelet were collected.
Their baseline HAS-BLED scores were calculated
using the clinical records and laboratory data at the
time of percutaneous coronary intervention.
The clinical outcomes were analysed up to 1 year
after percutaneous coronary intervention using the
electronic patient record. Events including ischemic
stroke, stent thrombosis, recurrent myocardial
infarction, bleeding and mortality were recorded.
Bleeding was classiﬁed into major or minor according to the International Society on Thrombosis
and Haemostasis (ISTH) bleeding scale. Major
bleeding was deﬁned as fatal bleeding or symptomatic bleeding in a critical area or organ, such as
intracranial, intraspinal, intraocular, retroperitoneal,
intra-articular or pericardial, or intramuscular with
compartment syndrome and/or bleeding causing a
fall in hemoglobin level of 2 g/dL or more, or
leading to transfusion of two or more units of whole
blood or red cells. Clinically relevant minor
bleeding was deﬁned as an acute or subacute clinically overt bleed that does not meet the criteria for a
major bleeding but prompts a clinical response, in
that it leads to at least one of the following:
 A hospital admission for bleeding, or
 A physician guided medical or surgical treatment for bleeding, or
 An unscheduled clinic visit, or
 A change in antithrombotic therapy (including
interruption or discontinuation of drugs)
The primary outcome is the difference in the
incidence of bleeding complications in the group of
patients with high HAS-BLED score (> or ¼ 3)
compared with the group of patients with low HASBLED score (<3) at 12 months.
Secondary outcomes included the difference in
the incidence of bleeding complications in the group
of patients receiving triple therapy compared with
the group of patients receiving dual anti-platelet
therapy; and the difference in the incidence of
bleeding complications in the group of patients
receiving non vitamin K oral anticoagulant
compared with the group of patients receiving
Warfarin in the triple therapy group.
This study was approved by the Research Ethics
Committee (Kowloon Central/Kowloon East Clusters) on December 31, 2018.
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Statistical analysis
Data was analyzed using the IBM SPSS Version 23
software. The baseline characteristics with high
HAS-BLED score (> or ¼ 3) or low HAS-BLED score
(<3), receiving triple therapy or dual anti-platelet
therapy were compared using the Chi-Square test
and Fisher's Exact test for categorical data, T test or
Mann Whitney U test for continuous data,
depending on whether the data is of normal distribution. Binary logistic regression analysis was used
to analyze the bleeding outcomes in the group of
patients with high HAS-BLED score (> or ¼ 3) or
low HAS-BLED score (<3), group of patients
receiving triple therapy or dual anti-platelet therapy
and group of patients receiving non-vitamin K oral
anticoagulants or Warfarin. A Kaplan-Meier curve
was constructed to illustrate the bleeding events of
the patients given triple therapy and dual antiplatelet therapy. The Receiver Operating Characteristics (ROC) Curve was constructed to assess the
performance of the HAS-BLED score in predicting
the bleeding risk using a continuous HAS-BLED
scale and using the HAS-BLED cut-off of 3.

Results
Baseline characteristics
186 patients were included in this study. 112 (60%)
subjects were discharged with dual anti-platelet
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therapy, 74 subjects (40%) were discharged with
triple therapy after percutaneous coronary intervention. The intended duration of triple therapy
varied from 1 months, 3 months, 6 months, 12
months to lifelong at the discretion of the operator.
The duration of dual anti-platelet therapy was 12
months or lifelong. Baseline characteristics
including age, sex, hypertension, diabetes, hyperlipidemia, smoking, alcohol, history of ischemic
stroke, history of intracranial hemorrhage, coronary
disease status, mean CHA2DS2-Vasc score, mean
HAS-BLED score and baseline renal function of the
two groups were listed in supplementary Table 1.
The mean HAS-BLED score was signiﬁcantly higher
in the triple therapy group than the dual antiplatelet group.
71 (38%) subjects had a high HAS-BLED score of 3
or above while 115 (62%) subjects had a low HASBLED score of 0e2. Using the cutoff of 3 was in line
with the recommendations by the latest ESC
guideline on atrial ﬁbrillation. Baseline characteristics including age, sex, hypertension, diabetes,
hyperlipidemia, smoking, alcohol, history of
ischemic stroke, history of intracranial hemorrhage,
renal function, and frequency of Warfarin and
NOAC use of the two groups were listed in Table 1.
The age was signiﬁcantly higher in the high HASBLED score group. There was signiﬁcantly more
hypertensive subjects in the high HAS-BLED score
group. There was signiﬁcantly higher proportion of
patients with history of ischemic stroke and

Table 1. Baseline characteristics of high HAS-BLED (3) and low HAS-BLED (0e2) group.
Median age
Sex
Hypertension
Diabetes mellitus
Hyperlipidemia
Smoking

Alcohol

History of ischemic stroke
History of intracranial bleeding
Baseline renal function
eGFR (ml/min/1.73m2)

Triple therapy
NOAC use
Warfarin use

High HAS-BLED  3 (N ¼ 71)

Low HAS-BLED score 0e2 (N ¼ 115)

p value

75
M ¼ 50 (70.4%)
F ¼ 21 (29.6%)
60 (84.5%)
35 (49.3%)
42 (59.2%)
Non-smoker ¼ 39 (55.0%)
Chronic smoker ¼ 5 (7.0%)
Ex-smoker ¼ 27 (38.0%)
Non-drinker ¼ 61 (85.9%)
Chronic drinker ¼ 3 (4.2%)
Ex-drinker ¼ 7 (9.9%)
25 (35.2%)
5 (7.0%)
eGFR >60 ¼ 42 (59.2%)
eGFR 30e59 ¼ 20 (28.2%)
eGFR 15e29 ¼ 2 (2.8%)
eGFR <15 ¼ 7 (9.9%)
38 (53.5%)
11 (15.5%)
27 (38.0%)

71
M ¼ 85 (73.9%)
F ¼ 30 (26.1%)
65 (56.5%)
50 (43.5%)
75 (65.2%)
Non-smoker ¼ 56 (48.7%)
Chronic smoker ¼ 18 (15.6%)
Ex-smoker ¼ 41 (35.7%)
Non-drinker ¼ 104 (90.4%)
Chronic drinker ¼ 5 (4.3%)
Ex-drinker ¼ 6 (5.2%)
5 (4.3%)
1 (0.9%)
eGFR >60 ¼ 80 (69.6%)
eGFR 30e59 ¼ 35 (30.4%)
eGFR 15e29 ¼ 0 (0%)
eGFR <15 ¼ 0 (0%)
36 (31.3%)
19 (16.5%)
17 (14.8%)

0.002a
0.616b

NOAC, non-vitamin K oral anticoagulant.
a
By Mann-Whitney U test.
b
By Chi-square test.
c
By Fisher's Exact test.

0.000b
0.453b
0.437b
0.220b

0.503b

0.000b
0.021c
0.156b
0.869b
0.144c
0.001c
0.003b
0.059b
0.058b
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Table 2. Bleeding complications in high and low HAS-BLED groups.

Any bleeding in 1 year
Major ISTH bleeding in 1 year
Clinically relevant minor
ISTH bleeding in 1 year

High HAS-BLED  3
(N ¼ 71)

Low HAS-BLED
0e2 (N ¼ 115)

Odds
ratio

95% conﬁdence
interval

p value

16
5
11

12
8
4

2.50
1.01
5.09

1.10e5.56
0.32e3.23
1.55e16.67

0.028
0.982
0.007

ISTH, International Society on Thrombosis and Haemostasis.

intracranial hemorrhage in the high HAS-BLED
score group. Regarding baseline renal function,
there were 7 subjects with estimated glomerular
ﬁltration rate <15ml/min/1.73m2 in the high HASBLED score group while there was 0 subjects with
such glomerular ﬁltration rate in the low HASBLED score group (p ¼ 0.001). Triple therapy was
prescribed more frequently in the high HAS-BLED
score group (53.5%) than the low HAS-BLED score
group (31.3%). There was no signiﬁcant difference in
the use of Warfarin and non-vitamin K oral anticoagulant between the two groups.
Primary outcome
The number of bleeding events stratiﬁed into triple therapy and dual anti-platelet therapy; high and
low HAS-BLED score were presented in supplementary Table 2 and supplementary Figure 1. 18
subjects had bleeding complications in the triple
therapy group and 10 subjects had bleeding

Figure 1. The Receiver Operating Characteristics (ROC) Curve using
continuous HAS-BLED scale in predicting bleeding events in the triple
therapy subgroup. TT, triple therapy; DAPT, dual anti-platelet therapy.

complications in the dual antiplatelet therapy group
within 1 year. Majority (16 out of 18, 89%) of subjects
in the triple therapy group suffered from bleeding
complications during the initial triple therapy
period, especially during the ﬁrst 3 months of triple
therapy, as shown in the Kaplan-Meier curve in
supplementary Figure 2. The incidence of bleeding
was signiﬁcantly higher in the triple therapy group
(OR 3.28, 95% CI, 1.42e7.59, p ¼ 0.006). There was
signiﬁcantly higher incidence of clinically relevant
minor ISTH bleeding in the triple therapy group
(OR 3.34, 95% CI, 1.09e10.22, p ¼ 0.034). There was
no signiﬁcant difference in the incidence of ISTH
major bleeding.
When comparing the bleeding events in the high
HAS-BLED score (3) and the low HAS-BLED score
groups, 16 subjects in the high HAS-BLED group
had bleeding events while 12 subjects in the low
HAS-BLED group had bleeding events within 1
year. The incidence of total bleeding was signiﬁcantly higher in the high HAS-BLED group (OR
2.50, 95% CI, 1.10e5.56, p ¼ 0.028), which was

Figure 2. The Receiver Operating Characteristics (ROC) Curve using
HAS-BLED cutoff of 3 in predicting bleeding events in the triple therapy
subgroup. TT, triple therapy; DAPT, dual anti-platelet therapy.
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mainly contributed by a signiﬁcantly higher incidence of clinically relevant minor ISTH bleeding
(OR 5.09, 95% CI, 1.55e16.67, p ¼ 0.007). There were
7 patients with estimated glomerular ﬁltration rate
<15 ml/min/1.73m2 in the high HAS-BLED score
group. None of them suffered from bleeding at 12month follow-up.
The triple therapy group was further stratiﬁed
into high and low HAS-BLED score in supplementary Table 4. The incidence of total bleeding
remained signiﬁcantly higher in the high HASBLED group than the low HAS-BLED group (OR
3.22, 95% CI, 1.01e10.27, p ¼ 0.028). In contrast,
there was no signiﬁcant difference in the incidence
of bleeding between high HAS-BLED and low HASBLED subjects receiving dual anti-platelet therapy,
as shown in supplementary Table 5.
In the cohort with high HAS-BLED score, the
incidence of total bleeding was signiﬁcantly higher
in subjects receiving triple therapy than those
receiving dual anti-platelet therapy (OR 5.20, 95% CI,
1.33e20.3, p ¼ 0.018), as shown in Table 6. Subgroup
analysis showed no signiﬁcant difference in the
1-year incidence of ISTH major or minor bleeding
between those receiving triple therapy and those
receiving dual anti-platelet therapy. In contrast, in
the cohort with low HAS-BLED score, there was no
signiﬁcant difference in bleeding between subjects
receiving triple therapy and those receiving dual
ant-platelet therapy, as shown in Table 7.
The ROC curve was constructed using the HASBLED score as a continuous variable (Figure 1) and
using a cutoff of 3 in the group of subjects receiving
triple therapy (Figure 2).
The area under the curve using a continuous
HAS-BLED scale was 0.673 (p ¼ 0.028, 95% CI,
0.535e0.811), demonstrating a statistically signiﬁcant and modest predictive value of HAS-BLED
score towards bleeding event in 1 year in patients
receiving triple therapy.
The area under the curve using a HAS-BLED cut
off of 3 was 0.638. (p ¼ 0.08, 95% CI, 0.493e0.782),
demonstrating statistically insigniﬁcant and modest
predictive value of HAS-BLED score 3 towards
bleeding events within 1 year in patients receiving
triple therapy.
Secondary outcomes
There was no signiﬁcant difference in incidence of
total bleeding, ISTH major and clinically relevant
ISTH minor bleeding between subjects taking
Warfarin and those taking non-vitamin K oral anticoagulants in the triple therapy group, as shown in
Table 8.
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Discussion
Comparison with previous studies
Despite being recommended by the latest ESC
guideline as a tool to assess bleeding risks in AF
patients undergoing PCI, previous reports or trials
to validate the performance of HAS-BLED score in
predicting bleeding outcomes are scarce. A prospective cohort study of 604 AF patients undergoing
percutaneous coronary intervention showed that
among patients at high bleeding risk (HAS-BLED
3), use of oral anticoagulants on discharge was
associated with a reduced rate of death and major
adverse cardiovascular events, but an increased risk
of major bleeding [5]. Another observational,
multicenter, prospective study of 929 AF patients
undergoing PCI aimed to evaluate the sensitivity
and speciﬁcity of the HAS-BLED, anticoagulation
and risk factors in atrial ﬁbrillation (ATRIA), modiﬁed Outpatient Bleeding Risk Index (MOBRI) and
reduction of atherothrombosis for continued health
(REACH) bleeding risk prediction scores and
assessed the rate of bleeding complications as
deﬁned by Bleeding Academic Research Consortium at 12-month follow up [6]. No signiﬁcant
difference were detected in the rates of any bleeding
or major bleeding events for low versus intermediate/high scores with each risk prediction tool. The
area under the ROC curve was 0.51 for HAS-BLED
score, indicating that the performance of HASBLED score in predicting bleeding complications
was poor.
Similar to previous studies, we use a HAS-BLED
score cut off of 3 to discriminate high and low
bleeding risks. The area under the ROC curve using
the HAS-BLED cutoff of 3 was 0.638, and the area
under the curve using a continuous HAS-BLED
scale was 0.673 demonstrating a better performance
of HAS-BLED score in predicting bleeding outcomes in patients receiving triple therapy than the
previous studies.
Our study demonstrated that there was a signiﬁcantly higher incidence of bleeding in those with
high HAS-BLED scores compared with low HASBLED scores in the triple therapy subgroup. This
reﬂects the ability of the HAS-BLED score in
discriminating which group of patients require
particular precaution to prevent bleeding especially
when prescribing triple therapy. In such group of
patients, the potential modiﬁable components of
HAS-BLED score (i.e. blood pressure, alcohol consumption, deranged liver and renal function) should
be corrected and the duration of triple therapy
should be kept as short as possible. A lower range of
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target international normalized ratio (i.e. 2.0e2.5)
should be considered to lower the risk of bleeding.
In patients with an extremely high HAS-BLED
score, dual therapy combining non-vitamin K oral
anticoagulants, P2Y12 inhibitor omitting aspirin can
be considered, as supported by recently published
trials, including the REDUAL-PCI [7] and the
recently published AUGUSTUS trial [12], showing a
lower incidence of bleeding in patients given dual
therapy without aspirin compared with triple therapy. There was no excess risk of stroke or stent
thrombosis.
Reﬂection of real world practice
Different from previous studies, more than half of
the patients (60%) in this study were prescribed dualantiplatelet therapy instead of triple therapy after
PCI. This reﬂects a deviation of real world clinical
practice from the guideline recommendations. There
are several possible reasons. First, this retrospective
cohort study included patients who underwent PCI
over 10 years from 2007 to 2017. Many of them were
managed in the early years when the 2006 ACC/
AHA/ESC recommendations of triple therapy for
these group of patients were still at class IIb [8].
These patients were prescribed high dose aspirin
plus clopidogrel instead of triple therapy. Even after
the update of the ESC and AHA guidelines, many
physicians tend to avoid prescribing triple therapy as
they worry about the potential risk of bleeding,
especially in the frail and elderly patients. Some
physicians preferred to start oral anticoagulation
after 1 year of dual anti-platelet therapy when the
P2Y12 inhibitors can be stopped. Patients' preference
is another reason explaining our observation in this
study. None of our patients were prescribed dual
therapy (oral anticoagulation plus P2Y12 inhibitor)
despite some of them had a very high HAS-BLED
score. Physicians still preferred to prescribe triple
therapy for at least 1 month as they were concerned
about the risk of recurrent myocardial infarction and
stent thrombosis, although no study had shown that
triple therapy has better protection against recurrent
myocardial infarction and stent thrombosis
compared with dual therapy.
The HAS-BLED score was not routinely calculated
and documented in most of the clinical records and
there was no association between the calculated
HAS-BLED score and the duration of triple therapy
prescribed by physicians. This reﬂects an underutilization of bleeding risk estimation scores in the
real clinical practice. The possible reason is that this
bleeding risk score is not universally accepted and
its accuracy was not well validated in large trials.

Despite the fact that a large proportion of patients were prescribed with dual anti-platelet
therapy without oral anticoagulation, there was no
signiﬁcant difference in the incidence of ischemic
stroke between the triple therapy and the dual antiplatelet therapy group at 12-month follow-up. In
our study, there was one subject suffering from
acute middle cerebral artery infarct 2 months after
stopping warfarin due to hemoptysis. Oral anticoagulation therapy has been proven to be superior
in terms of stroke prevention over dual antiplatelet therapy in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of
Vascular Events (ACTIVE-W) study [10]. A recent
meta-analysis including 14 observational studies
showed that triple therapy reduced the risk of
ischemic stroke and stent thrombosis with an
acceptable major bleeding risk compared with dual
anti-platelet therapy [11].
Bleeding in Warfarin and non-vitamin K oral
anticoagulants
Only one previous retrospective study done in
USA compared Warfarin and full dose non-vitamin
K oral anticoagulants in triple therapy [9]. It showed
a signiﬁcantly higher risk of gastrointestinal, intracranial and other bleeding events in subjects
receiving Warfarin dual anti-platelet therapy
compared with those receiving non-vitamin K oral
anticoagulants with dual anti-platelet therapy. Our
study did not show any signiﬁcant difference in
bleeding between subjects receiving Warfarin and
subjects receiving non-vitamin K oral antagonists as
part of triple therapy. The lack of difference in our
study may be due to a small sample size.
Limitation and pitfalls
Our study has several limitations. First, the retrospective nature of this study is prone to selection
bias due to lack of randomization. Second, the
calculation of risk scores (i.e. CHA2DS2-Vasc, HASBLED) in each individual subject depends on accurate and comprehensive clinical recording by the
physicians. Some of these data may be incorrect and
incomplete causing information bias. Blood pressure
record was scarce and sometimes missing requiring
reference to previous blood pressure measurement.
White coat hypertension may also be present at any
time causing incorrect HAS-BLED scoring. Labile
INR, one of the important components in the HASBLED score, cannot be accurately estimated in many
subjects because most of them were not taking
Warfarin and many of those taking Warfarin had

J HK COLL CARDIOL 2022;29(2):75e84

infrequent INR checking, causing inaccurate time in
therapeutic range calculation. The smoking and
alcohol drinking status may also be outdated at the
time of data collection. Classiﬁcation of bleeding
outcomes requires detailed recording of the
bleeding events in clinical records. Inaccurate
recording of such events may cause misclassiﬁcation
of bleeding outcomes. Third, the dose of dual antiplatelet therapy and non-vitamin K oral anticoagulants prescribed was not the same among subjects.
The time within therapeutic range in subjects
receiving warfarin varied greatly. Drug compliance
can also affect the bleeding outcomes. Fourth, the
sample size of our study was small. Stratiﬁcation of
subjects during data analysis further reduced the
statistical power and thus the results are subjected to
large random error, as indicated by the wide 95%
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conﬁdence interval of the odds ratio. Fifth, different
from the latest ESC guideline, there were no patients
who received dual therapy (i.e. anti-coagulant plus
P2Y12 inhibitor) after PCI in our study.

Conclusion
HAS-BLED score is a simple and useful tool to
predict bleeding risk in AF patients who undergo
percutaneous coronary intervention. It has modest
performance in predicting bleeding in patients
who receive triple therapy with the area under
ROC curve of 0.638. Utilization of this score
together with other clinical factors can guide physicians in choosing the optimal combination and
duration of antithrombotic regime in this group of
patients.

Appendix.
Supplementary Figures

Figure 1. 3D bar chart illustrating the bleeding events in different strata. TT, triple therapy; DAPT, dual anti-platelet therapy.
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Figure 2. Kaplan Meier plot of bleeding events following PCI in the triple therapy and dual anti-platelet therapy subgroups. TT, triple therapy; DAPT,
dual anti-platelet therapy; PCI, percutaneous coronary intervention.

Supplementary Table
Table 1. Baseline characteristics of triple therapy and dual-antiplatelet therapy group.
Median age
Sex
Hypertension
Diabetes mellitus
Hyperlipidemia
Smoking

Alcohol

Stable CAD
ACS
History of ischemic stroke
History of intracranial bleeding
Mean CHA2DS2-Vasc
Mean HAS-BLED
Baseline renal function

Triple therapy group (N ¼ 74)

Dual anti-platelet therapy group (N ¼ 112)

p value

72.5
M ¼ 56 (75.7%)
F ¼ 18 (24.3%)
51 (68.9%)
33 (44.6%)
45 (60.8%)
Non-smoker ¼ 37 (50%)
Chronic smoker ¼ 8 (10.8%)
Ex-smoker ¼ 29 (39.1%)
Non-drinker ¼ 64 (86.5%)
Chronic drinker ¼ 4 (5.4%)
Ex-drinker ¼ 6 (8.1%)
42 (56.8%)
32 (43.2%)
13 (17.6%)
2 (2.7%)
3.66
2.57
eGFR >60 ¼ 47 (63.5%)
eGFR 30e59 ¼ 24 (32.4%)
eGFR 15e29 ¼ 2 (2.7%)
eGFR <15 ¼ 1 (1.4%)

73
M ¼ 79 (70.5%)
F ¼ 33 (29.5%)
71 (63.3%)
52 (46.4%)
72 (64.2%)
Non-smoker ¼ 58 (52%)
Chronic smoker ¼ 15 (13.3%)
Ex-smoker ¼ 39 (34.8%)
Non-drinker ¼ 101 (90.2%)
Chronic drinker ¼ 4 (3.6%)
Ex-drinker ¼ 7 (6.2%)
60 (53.6%)
52 (46.4%)
17 (15.2%)
4 (3.6%)
3.56
2.21
eGFR >60 ¼ 75 (67.0%)
eGFR 30e59 ¼ 31 (27.7%)
eGFR 15e29 ¼ 0 (0%)
eGFR <15 ¼ 6 (5.3%)

0.363a
0.504b

CAD, coronary artery disease; ACS, acute coronary syndrome.
a
By Mann-Whitney U test.
b
By Chi-square test.
c
By Fisher's Exact tes.

0.751b
0.881b
0.645b
0.775b

0.769b

0.764b
0.688b
0.549c
0.743a
0.003a
0.640b
0.514b
0.157c
0.246c
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Table 2. Bleeding events stratiﬁed by triple therapy and dual anti-platelet therapy and HAS-BLED score categories.

Any Bleeding
ISTH major bleeding
ISTH minor bleeding

No
Yes
No
Yes
No
Yes

Triple therapy (N ¼ 74)

Dual anti-platelet therapy (N ¼ 112)

HAS-BLED score category

HAS-BLED score category

>or ¼ 3 (N ¼ 38)

0-2 (N ¼ 36)

>or ¼ 3 (N ¼ 33)

0-2 (N ¼ 79)

25
13
33
5
30
8

31
5
33
3
34
2

30
3
33
0
30
3

72
7
74
5
77
2

ISTH, International Society on Thrombosis and Haemostasis.

Table 3. Stroke and bleeding complications in triple therapy and dual anti-platelet therapy group.

Ischemic stroke in 1 year
Any bleeding in 1 year
Any bleeding during triple therapy period
Major ISTH bleeding in 1 year
Clinically relevant minor
ISTH bleeding in 1 year

TT group
(N ¼ 74)

DAPT group
(N ¼ 112)

Odds
ratio

95% conﬁdence
interval

p value

1
18
16
8
10

7
10
N/A
5
5

0.21
3.28

0.03e1.72
1.42e7.59

0.143
0.006

2.59
3.34

0.81e8.26
1.09e10.22

0.107
0.034

ISTH, International Society on Thrombosis and Haemostasis; TT, triple therapy, DAPT, dual anti-platelet therapy.

Table 4. Bleeding complications in high and low HAS-BLED group receiving triple therapy.

Any bleeding in 1 year
Major ISTH bleeding in 1 year
Clinically relevant minor
ISTH bleeding in 1 year

High HAS-BLED
 3 on TT (N ¼ 38)

Low HAS-BLED
0e2 on TT (N ¼ 36)

Odds ratio

95% conﬁdence
interval

p value

13
5
8

5
3
2

3.22
1.67
4.53

1.01e10.27
0.37e7.55
0.89e23.03

0.028
0.507
0.068

ISTH, International Society on Thrombosis and Haemostasis.

Table 5. Bleeding complications in high and low HAS-BLED group receiving dual antiplatelet therapy.

Any bleeding in 1 year
Major ISTH bleeding in 1 year
Clinically relevant minor
ISTH bleeding in 1 year

High HAS-BLED
 3 on DAPT (N ¼ 33)

Low HAS-BLED 0e2
on DAPT (N ¼ 79)

Odds
ratio

95% conﬁdence
interval

p value

3
0
3

7
5
2

1.03
0.20
3.85

0.25e4.25
0.01e3.92
0.61e24.20

0.969
0.291
0.151

ISTH, International Society on Thrombosis and Haemostasis; DAPT, dual anti-platelet therapy.
Table 6. Bleeding complications in high HAS-BLED group receiving triple or dual antiplatelet therapy.
High HAS-BLED  3

TT
(N ¼ 38)

DAPT
(N ¼ 33)

Odds
ratio

95% conﬁdence
interval

p value

Any bleeding in 1 year
Major ISTH bleeding in 1 year
Clinically relevant minor
ISTH bleeding in 1 year

13
5
8

3
0
3

5.20
13.4
2.67

1.33e20.3
0.69e258.60
0.64e11.03

0.018
0.086
0.176

ISTH, International Society on Thrombosis and Haemostasis; TT, triple therapy, DAPT, dual anti-platelet therapy.
Table 7. Bleeding complications in low HAS-BLED group receiving triple or dual antiplatelet therapy.
Low HAS-BLED 0-2

TT
(N ¼ 36)

DAPT
(N ¼ 79)

Odds
ratio

95% conﬁdence
interval

p value

Any bleeding in 1 year
Major ISTH bleeding in 1 year
Clinically relevant minor
ISTH bleeding in 1 year

5
3
2

7
5
2

1.66
1.35
2.27

0.49e5.63
0.30e5.96
0.31e16.75

0.417
0.696
0.423

ISTH, International Society on Thrombosis and Haemostasis; TT, triple therapy, DAPT, dual anti-platelet therapy.
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Table 8. Bleeding complications in triple therapy subjects receiving Warfarin or non-vitamin K oral anticoagulants.

Any bleeding in 1 year
Major ISTH bleeding in 1 year
Clinically relevant minor
ISTH bleeding in 1 year

Warfarin
(N ¼ 44)

Non-vitamin K oral
anticoagulant (N ¼ 30)

Odds
ratio

95% conﬁdence
interval

p value

12
4
8

6
4
2

1.50
0.65
3.11

0.49e4.57
0.15e2.83
0.61e15.8

0.476
0.566
0.171

ISTH, International Society on Thrombosis and Haemostasis.
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